Bioinformatics USA | Kisaco Research
Systems infrastructure, data management and machine learning for life sciences and healthcare informatics labs
Boston, USA
7-9 May, 2019
Download Agenda
The Audience
Register

Why Attend

Modern day scientists are collecting overwhelming volumes of data – genomic data, phenotypic data, microbiome, exomes, clinical data, population health data and more. The rich and complex data sets now available to health, academic and life science professionals offer tremendous opportunity for future healthcare and drug discovery. The sheer volume coupled with the Tech Revolution is driving change to bioinformatics infrastructure, data visualisation and data analysis. Bioinformatics USA explores bioinformatics infrastructure and best practice data management for life science and healthcare professionals, including a full day on AI and machine learning. You’ll leave with actionable ideas to improve your data management infrastructure, new relationships throughout life sciences, healthcare and technology companies and insights into the next generation of AI-driven computational biology.

10 things you will learn...

1. How to facilitate secure data sharing and improve data visualisation

2. Making the business case for building vs buying informatics infrastructure

3. Comparative advantages of Saas vs building premium hardware

4. How to address regulatory concerns using in silico results

5. How to use AI to analyse real-world outcomes of clinical trials

6. How to develop a state-of-the-art bioinformatics workforce and workflow

7. How to handle and maintain data downstream

8. Assess comparative benefits of available cloud infrastructure for life sciences and healthcare

9. Is quantum computing actually a reality for life sciences and what will it help us do?

10. How to manage the people conundrum: helping bioinformaticians and biologists find a common language

Who Will Be There

20%
Healthcare informatics professionals
20%
Big pharma
20%
Data-driven biotechs
15%
Data management platforms
15%
Cloud and Saas providers
10%
Systems integrators and consultants

Healthcare informatics professionals

Big pharma

Data-driven biotechs

Data management platforms

Cloud and Saas providers

Systems integrators and consultants

The Speakers

 

Dr Anthony Philippakis M.D., Ph.D.

Venture Partner
Google Ventures

Anthony Philippakis is the Chief Data Officer of the Broad Institute of MIT and Harvard, where he is also an institute scientist.

Dr Anthony Philippakis M.D., Ph.D.

Venture Partner
Google Ventures

Anthony Philippakis is the Chief Data Officer of the Broad Institute of MIT and Harvard, where he is also an institute scientist.

Philippakis is committed to bridging the gap between data sciences and medicine. He is a cardiologist at Brigham and Women’s Hospital, where his primary focus is caring for patients with rare genetic cardiovascular diseases. At the Broad Institute he directs the Data Sciences Platform, an organization of over 100 software engineers and computational biologists that develops software for analyzing genomic and clinical data. In addition to his roles at the Broad Institute and Brigham and Women’s Hospital, Philippakis is a Venture Partner at GV, focusing on machine learning, distributed computing, and genomics.

Philippakis received his M.D. from Harvard Medical School and completed a Ph.D. in biophysics at Harvard. As an undergraduate, he studied mathematics at Yale University, and later completed the Part III (equivalent to M.Phil) in mathematics at Cambridge University. 

 

John Baldoni

Senior Vice President, In silico Drug Discovery
GlaxoSmithKline

John Baldoni

Senior Vice President, In silico Drug Discovery
GlaxoSmithKline
 

Dr David Fenstermacher

Vice President, R&D Bioinformatics
Medimmune

Dr. David Fenstermacher is currently the Vice President R&D-Bioinformatics at Medimmune, LLC. With more than 30 years of research experience as a molecular biologist and bioinformaticist, he has held several academic appointments at multiple universities and led several national and international informatics projects.

Dr David Fenstermacher

Vice President, R&D Bioinformatics
Medimmune

Dr. David Fenstermacher is currently the Vice President R&D-Bioinformatics at Medimmune, LLC. With more than 30 years of research experience as a molecular biologist and bioinformaticist, he has held several academic appointments at multiple universities and led several national and international informatics projects.

During his twenty years in bioinformatics, David designed and directed the implementation of numerous bioinformatics and biomedical informatics distributed computing systems to support basic, translational and clinical research, including multiple institution research projects. He has also designed data warehouses that integrate patient-level clinical data, genomics (genome-wide association studies, massively parallel sequencing, array-based technologies) and other ‘omics data to support studies focused on cancer and other human diseases.  Most recent research is focused on developing a federated semantic approach for data integration to support target identification/validation and precision medicine.

David received his PhD in Molecular Biology and Genetics from the University of North Carolina at Chapel Hill.   

 

 

Dr Kelly Zou

Vice President, Head of Medical Analytics and Insights, R&D and Medical, Upjohn Division
Pfizer

Kelly Zou, Ph.D., PStat® is Vice President, Medical Analytics & Insights, R&D and Medical, Upjohn Division, Pfizer Inc. She is an elected Fellow of the American Statistical Association and an Accredited Professional Statistician. Previously, she was Senior Director, Global Real World Evidence Center of Excellence and Senior Director, Statistical Center for Outcomes, Real World & Aggregate Data at Pfizer. She was Associate Professor of Radiology at Harvard Medical School, as well as Director of Biostatistics at its affiliated teaching hospitals.

Dr Kelly Zou

Vice President, Head of Medical Analytics and Insights, R&D and Medical, Upjohn Division
Pfizer

Kelly Zou, Ph.D., PStat® is Vice President, Medical Analytics & Insights, R&D and Medical, Upjohn Division, Pfizer Inc. She is an elected Fellow of the American Statistical Association and an Accredited Professional Statistician. Previously, she was Senior Director, Global Real World Evidence Center of Excellence and Senior Director, Statistical Center for Outcomes, Real World & Aggregate Data at Pfizer. She was Associate Professor of Radiology at Harvard Medical School, as well as Director of Biostatistics at its affiliated teaching hospitals. She was Associate Director of Rates at Barclays Capital. She received both MA and PhD degrees in Statistics from the University of Rochester, following a BA in Mathematics (Summa Cum Laude), with a Minor in Physics. She completed her Postdoctoral Fellowship at Harvard. Her research interests include healthcare policy, big data, and outcomes research, with over 140 professional articles and 4 books. She has played several leadership roles: Chair, Committee of Presidents of Statistical Societies Awards; Chair, Statistical Partnerships among Academe, Industry, and Government Committee, American Statistical Association (ASA); Chair, ASA Health Care Policy Statistics Section; Vice Chair, ASA Committee on Applied Statisticians; Member, Board of Directors and Publications Committee, International Chinese Statistical Association. She was featured as an Outstanding Woman in Data Analytics by Forbes, an Inspirational Women in Statistics & Data Science by Wiley and the Royal Statistical Society, and an Accomplished Woman in Statistics and Data Science by the ASA.

 

Dr Ramesh Dursuvala

Vice President and Information Officer, Research Labs
Eli Lilly

As the Information Officer for Research, Ramesh Durvasula is responsible for all of the IT and informatics capabilities that support the drug discovery efforts of Lilly Research Labs. 

Dr Ramesh Dursuvala

Vice President and Information Officer, Research Labs
Eli Lilly

As the Information Officer for Research, Ramesh Durvasula is responsible for all of the IT and informatics capabilities that support the drug discovery efforts of Lilly Research Labs. 

Dr. Durvasula has focused his career on the intersection of life science and informatics.  For more than a decade, he built award-winning technology platforms for Bristol-Myers-Squibb (BMS) research labs.  Most recently, Ramesh was Executive Director of Discovery IT and Automation at BMS.  He has held a variety of leadership roles during his 12-year tenure at BMS.  He successfully led his team through delivery of various IT strategies and roadmaps for biologics, laboratory modernization, translational R&D, in-vivo excellence, high-throughput workflows and leveraging data for quantitative decision making.  He is an active leader in many industry forums, such as the Pistoia Alliance and the Allotrope Foundation. Prior to BMS, he spent several years at Tripos, a computational chemistry software firm.  Ramesh earned his BA in Chemistry and PhD in Biochemistry & Molecular Genetics from the University of Virginia.

 

Dr Victoria Gamerman

Head of US Informatics and Health Analytics
Boehringer Ingelheim

Dr Victoria Gamerman

Head of US Informatics and Health Analytics
Boehringer Ingelheim
 

Mark Davies

Vice President Biomedical Informatics
Benevolent AI

Mark Davies

Vice President Biomedical Informatics
Benevolent AI
 

Dr Chip Petricoin

Chief Scientific Officer
Perthera

Dr. Emanuel F Petricoin is the Chief Science Officer and Co-Founder of Perthera, Inc., Perthera is a leading precision medicine company that empowers all cancer patients and oncologists globally with the most comprehensive molecular profiling and data analytics process. Dr. Petricoin has been the Co-Director of the Center for Applied Proteomics and Molecular Medicine at George Mason University since 2005, where he is a University Professor.

Dr Chip Petricoin

Chief Scientific Officer
Perthera

Dr. Emanuel F Petricoin is the Chief Science Officer and Co-Founder of Perthera, Inc., Perthera is a leading precision medicine company that empowers all cancer patients and oncologists globally with the most comprehensive molecular profiling and data analytics process. Dr. Petricoin has been the Co-Director of the Center for Applied Proteomics and Molecular Medicine at George Mason University since 2005, where he is a University Professor. Prior to this position, he served as Co-Director of the FDA-NCI Clinical Proteomics Program and a Senior Investigator within the Center for Biologics Evaluation and Research at the FDA from 1993-2005. He has authored over 400 peer-reviewed publications and invited reviews with an H Factor of 98, and is on the editorial board of over 10 high impact journals. He has authored over 45 book chapters, is a Senior Editor for Cancer Epidemiology Biomarkers and Prevention and on the editorial board of JCO Precision Oncology, Nature Precision Oncology, Proteomics, Biomedical Microdevices, Proteomics-Clinical Applications, Proteomics-Protocols, Molecular, Carcinogenesis, Journal of Personalized Medicine and Dr. Petricoin is a founding member of the Human Proteomic Organization (HUPO). He has received numerous awards including the University Professorship at George Mason University, the NIH Director’s Award, FDA Distinguished Scientist Award, 2015 Innovator of the Year Award, GAP50 Top Virginia Entrepreneurs, Nifty 50 Award, American Society of Cytopathology Basic Research Award, the Roche Diagnostics/CLAS Distinguished Scientist Award and the Harvard University Leading Edge Award and is a Kentucky Colonel.

 

Dr Shahar Keinan

Chief Scientific Officer
Cloud Pharmaceuticals

Dr. Shahar Keinan is the Chief Scientific Officer and co-founder of Cloud Pharmaceuticals. She has over 20 years of extensive experience in the field of computational and theoretical chemistry. Shahar has received a Ph.D.

Dr Shahar Keinan

Chief Scientific Officer
Cloud Pharmaceuticals

Dr. Shahar Keinan is the Chief Scientific Officer and co-founder of Cloud Pharmaceuticals. She has over 20 years of extensive experience in the field of computational and theoretical chemistry. Shahar has received a Ph.D. in theoretical chemistry from The Hebrew University of Jerusalem and has numerous papers and presentations in the fields of in-silico drug design and discovery, as well as molecular materials design and computational methods development. She has been instrumental in the development of Cloud Pharmaceuticals’ novel Quantum Molecular Design process since its inception at Duke University.

 

Dr Slava Akmaev

Senior Vice President & Chief Analytics Officer
BERG Healthcare

Slava Akmaev, Ph.D., is the Senior Vice President and Chief Analytics Officer at BERG, leading the Analytics division with over 18 years of industry experience. He is responsible for supporting BERG’s drug and diagnostic development programs with data science efforts using BERG’s proprietary artificial intelligence (AI) platform, bAIcis®. Dr. Akmaev is an advocate for the application of AI tools in digital healthcare and is a frequent speaker at AI industry events. Dr.

Dr Slava Akmaev

Senior Vice President & Chief Analytics Officer
BERG Healthcare

Slava Akmaev, Ph.D., is the Senior Vice President and Chief Analytics Officer at BERG, leading the Analytics division with over 18 years of industry experience. He is responsible for supporting BERG’s drug and diagnostic development programs with data science efforts using BERG’s proprietary artificial intelligence (AI) platform, bAIcis®. Dr. Akmaev is an advocate for the application of AI tools in digital healthcare and is a frequent speaker at AI industry events. Dr. Akmaev is an inventor on 10+ pending and issued patents and an author on more than 20 peer-reviewed publications, book chapters, and 100+ presentations/ posters.

Prior to his role at BERG, Dr. Akmaev was the Scientific Associate Director at Genzyme Genetics where he launched multiple commercial diagnostic products. While at Genzyme R&D, he led the development of novel statistical approaches for high-throughput “omics” data and performed analytical work in genomics and genetics.

Dr. Akmaev published numerous manuscripts in genomics and was one of the early developers of analytical methodology around high-throughput molecular data. He co-authored the publication of the Long SAGE™ technology, “Using the transcriptome to annotate the genome” in Nature Biotechnology.

Dr. Akmaev holds a Ph.D. in Applied Mathematics from the University of Colorado at Boulder.

 

Victor Hanson-Smith

Head of Computational Biology
Verge Genomics

Victor is one of the world's leaders in mathematical modeling of eukaryotic genome evolution. He has co-authored over 11 publications in peer-reviewed journals such as Nature and Science; his work has been featured in the NYTimes and Washington Post. He received his Ph.D. in computer science from the University of Oregon, and completed his postdoc in Sandy Johnson's group at UCSF. Additionally, he is a full-stack Django web developer on Amazon Web Services, with 15 years experience engineering in C/C++, Python, and Java.

Victor Hanson-Smith

Head of Computational Biology
Verge Genomics

Victor is one of the world's leaders in mathematical modeling of eukaryotic genome evolution. He has co-authored over 11 publications in peer-reviewed journals such as Nature and Science; his work has been featured in the NYTimes and Washington Post. He received his Ph.D. in computer science from the University of Oregon, and completed his postdoc in Sandy Johnson's group at UCSF. Additionally, he is a full-stack Django web developer on Amazon Web Services, with 15 years experience engineering in C/C++, Python, and Java.

 

Dr Gustavo Stolovitzky

Program Director, Translational Systems Biology and Nanobiotechnology
Thomas J. Watson Research Center

Dr Gustavo Stolovitzky

Program Director, Translational Systems Biology and Nanobiotechnology
Thomas J. Watson Research Center
 

Dr Jinghui Zhang

Chair of Computational Biology
St Jude Children’s Research Hospital

Jinghui Zhang, Ph.D., is chair of the Department of Computational Biology at St. Jude Children’s Research Hospital. She holds the St. Jude Endowed Chair in Bioinformatics.

Dr Jinghui Zhang

Chair of Computational Biology
St Jude Children’s Research Hospital

Jinghui Zhang, Ph.D., is chair of the Department of Computational Biology at St. Jude Children’s Research Hospital. She holds the St. Jude Endowed Chair in Bioinformatics.

Dr. Zhang began working in genomics as a second-year graduate student, which sparked her interest in investigating how genes contribute to the development of diseases like cancer. She joined St. Jude in 2010, leading the genomic analysis for the Pediatric Cancer Genome Project (PCGP) and the creation of new computational and visualization tools that have been adopted by researchers worldwide.

Her research in the genomic landscape of pediatric cancer has led to new directions in research involving high-risk leukemia, brain and solid tumors. She sees the importance of sharing data gained from her collaboration with other pediatric cancer research institutes. The sharing of information can help advance research not only for pediatric cancer, but for genetic research in other diseases.

Before joining St. Jude, Dr. Zhang led genetic variation analysis of the first assembled human genome. She also contributed to key discoveries in the pilot phases of the National Cancer Institute’s Cancer Genome Atlas Project and led the pan-cancer analysis of the Therapeutically Applicable Research to Generate Effective Treatment (TARGET) initiative which has unveiled striking difference in the genomic landscape of pediatric versus adult cancer.

Dr. Zhang received her undergraduate degree from Fu Dan University in Shanghai and her doctorate from the University of Connecticut in Storrs, Conn.

 

 

Prof Robert L Grossman

Chief Research Informatics Officer, Division of the Biological Sciences
University of Chicago

Prof Robert L Grossman

Chief Research Informatics Officer, Division of the Biological Sciences
University of Chicago
 

Dr Vivien Bonazzi

Senior Advisor for Data Science / Project Leader
National Institute of Health / NIH Data Commons

Dr. Vivien Bonazzi joined the Office of Strategic Coordination in 2017 leading the NIH Data Commons, part of the broader New Models of Data Stewardship program.

Dr Vivien Bonazzi

Senior Advisor for Data Science / Project Leader
National Institute of Health / NIH Data Commons

Dr. Vivien Bonazzi joined the Office of Strategic Coordination in 2017 leading the NIH Data Commons, part of the broader New Models of Data Stewardship program.

Dr. Bonazzi has been advising the NIH Office of the Director (OD) on data science-related issues since 2014. Before joining the NIH OD, she served as program director for the Computational Biology and Bioinformatics program for the NIH National Human Genome Research Institute (NHGRI). 

Dr. Bonazzi was also part of the Human Microbiome Project (HMP) a trans-NIH Common Fund Initiative whose aims are to characterize the microbial communities found at several different sites on the human body and to analyze the role of these microbes in human health and disease. Prior to joining NHGRI, she was a Senior Associate at Booz Allen Hamilton providing strategic development expertise in data science and also managing several genome and protein bioinformatics projects for NIH and biomedical companies. She has also held the positions of R&D Director for Bioinformatics at Invitrogen and Director of Gene Discovery at Celera Genomics where she was part of the team that sequenced and annotated the Human, Mouse and Drosophila genomes. Dr. Bonazzi received a BSc in Medical Laboratory Science from the University of Canberra, Australia, a MSc (prelim) in Pharmacology from the University of Melbourne, Australia and a PhD in Molecular Pharmacology and Computational Biology also from the University of Melbourne.

 

Peter Goodhand

Chief Executive Officer
GA4GH

Peter Goodhand is a leader in the global health sector as a senior executive and board member.

 

Goodhand played a key role in the creation of the Global Alliance for Genomics and Health (GA4GH) and was appointed as its founding Executive Director in 2014, and as Chief Executive Officer in 2018. From May 2016 to April 2018, he also served as the President of the Ontario Institute for Cancer Research (OICR).

Peter Goodhand

Chief Executive Officer
GA4GH

Peter Goodhand is a leader in the global health sector as a senior executive and board member.

 

Goodhand played a key role in the creation of the Global Alliance for Genomics and Health (GA4GH) and was appointed as its founding Executive Director in 2014, and as Chief Executive Officer in 2018. From May 2016 to April 2018, he also served as the President of the Ontario Institute for Cancer Research (OICR).

Prior to the GA4GH and OICR, he was the President and Chief Executive Officer of the Canadian Cancer Society, Canada's largest health charity. Before joining the charitable sector, Goodhand had a 20 year career in the global medical technology industry, including strategic leadership roles with multinational healthcare companies such as American Cyanamid and Johnson & Johnson; Board Chair and President of Canada’s Medical Device Industry association (MEDEC); and as the founding Managing Director and then Board Chair of the Health Technology Exchange (HTX).

Goodhand is currently a member of the Occupational Cancer Research Centre Steering Committee, Co-chair of the Medical and Scientific Advisory Board of Global Genes, Co-chair of the International 100K+ Cohorts Consortium (IHCC), and a member of the of the Global Genomic Medicine Collaboration (G2MC) Steering Committee.

He chaired the Government of Canada’s Expert working group on the future of medical isotope production, and was a member of the Canadian delegation to the UN summit on non-communicable diseases.

 

Mike Kellen

Chief Technical Officer
Sage Bionetworks

Mike Kellen

Chief Technical Officer
Sage Bionetworks
 

Mason Victors

Chief Technology Officer
Recursion Pharmaceuticals

Mason earned his MS in Mathematics from BYU, where he focused on developing new approaches to identifying individuals at-risk for chronic kidney disease. After an internship with the NSA, being unable to decide between becoming a spook or pursuing a PhD he chose the obvious route: join a start-up instead. As part of a small team of data scientists at Red Brain Labs and later Savvysherpa, he developed algorithms to mine unstructured medical records, analyze human behavior through cell phone logs, and simulate complex call centers.

Mason Victors

Chief Technology Officer
Recursion Pharmaceuticals

Mason earned his MS in Mathematics from BYU, where he focused on developing new approaches to identifying individuals at-risk for chronic kidney disease. After an internship with the NSA, being unable to decide between becoming a spook or pursuing a PhD he chose the obvious route: join a start-up instead. As part of a small team of data scientists at Red Brain Labs and later Savvysherpa, he developed algorithms to mine unstructured medical records, analyze human behavior through cell phone logs, and simulate complex call centers. Apart from work, he loves spending time with his wife and two daughters.

 

Dr Eric Perakslis

Chief Scientific Officer
Datavant

Eric is currently Chief Science Officer at Datavant, an innovative new company with the mission to organize the worlds healthcare data. Eric is also Visiting Scientist in the Department of Biomedical Informatics at Harvard Medical School and a frequent volunteer advisor to Médecins Sans Frontières and other international aid and relief NGOs.

Dr Eric Perakslis

Chief Scientific Officer
Datavant

Eric is currently Chief Science Officer at Datavant, an innovative new company with the mission to organize the worlds healthcare data. Eric is also Visiting Scientist in the Department of Biomedical Informatics at Harvard Medical School and a frequent volunteer advisor to Médecins Sans Frontières and other international aid and relief NGOs. Most recently Eric was Senior Vice President and Head of the Takeda R&D Data Science Institute where he built an integrated institute of more than 165 multi-disciplinary data scientists serving all aspects of biopharmaceutical R&D and digital health. Prior to Takeda, Eric was the Executive Director of the Center for Biomedical Informatics and the Countway Library of Medicine, an Instructor in Pediatrics at Harvard Medical School and a faculty member of the Children’s Hospital Informatics Program at Boston Children’ Hospital. Eric has a PhD in chemical and biochemical engineering from Drexel University and also holds B.S.ChE and M.S. degrees in chemical engineering.

 

Dr Stacie Calad-Thomson

Chief Operating Officer
ATOM Consortium

Stacie Calad-Thomson is Chief Operating Officer of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, a new public-private partnership that aims to accelerate the discovery of effective cancer therapies through integration of high-performance computing, diverse biological data, and emerging biotechnologies. Founding consortium members include the Department of Energy’s Lawrence Livermore National Laboratory, GSK, the National Cancer Institute’s Frederick National Laboratory for Cancer Research, and the University of California, San Francisco.

Dr Stacie Calad-Thomson

Chief Operating Officer
ATOM Consortium

Stacie Calad-Thomson is Chief Operating Officer of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, a new public-private partnership that aims to accelerate the discovery of effective cancer therapies through integration of high-performance computing, diverse biological data, and emerging biotechnologies. Founding consortium members include the Department of Energy’s Lawrence Livermore National Laboratory, GSK, the National Cancer Institute’s Frederick National Laboratory for Cancer Research, and the University of California, San Francisco. The goal of the consortium is to create a new paradigm of drug discovery that would reduce the time from an identified drug target to clinical candidate from the current approximately six years to just 12 months. Stacie has worked for GSK, starting as a chemist and moving into business strategy and operations roles within R&D Platform Technology & Sciences, where she led several change initiatives. She has a BS (UC Berkeley) and a PhD (UC Irvine) in chemistry.

The Agenda

Download the agenda for Bioinformatics Infrastructure USA

Watch highlights from the AI Hardware Summit 2018

 

Register your interest

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

Become a Sponsor

Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Venue

Boston, USA

Accessibility:

We are committed to making our event accessible for everyone. If you are traveling for the event, Cloud of Goods provides mobility scooter rentals, wheelchair rentals, and other mobility solutions. They will deliver directly to you at the event, your hotel, the airport, or any other place of your choosing. Event attendees will receive a 20% discount when using the code: RENTGEAR032

Visit: https://www.cloudofgoods.com/ 

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

Tuesday, December 18, 2018 to Friday, March 1, 2019
PHARMA & BIOTECH SUPER EARLY BIRD PRICE
$1,299
Register and pay by March 1, 2019. Save $500.
2 day conference pass
Must have an active drug pipeline
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Tom Ledward, [email protected]
Tuesday, December 18, 2018 to Friday, March 1, 2019
PHARMA & BIOTECH SUPER EARLY BIRD PRICE INCLUDING MACHINE LEARNING DAY
$1,999
Register and pay by March 1, 2019. Save $600.
3 day conference pass including Machine Learning Day
Must have an active drug pipeline
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Tom Ledward, [email protected]
Tuesday, December 18, 2018 to Friday, March 1, 2019
VENDORS/SERVICE PROVIDERS SUPER EARLY BIRD PRICE
$1,499
Register and pay by March 1, 2019. Save $600.
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Tom Ledward, [email protected]
Tuesday, December 18, 2018 to Friday, March 1, 2019
VENDORS/SERVICE PROVIDERS SUPER EARLY BIRD PRICE INCLUDING MACHINE LEARNING DAY
$2,299
Register and pay by March 1, 2019. Save $600.
3 day conference pass including Machine Learning Day
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Tom Ledward, [email protected]
Tuesday, December 18, 2018 to Friday, March 1, 2019
ACADEMIA, GOVERNMENT AND HEALTHCARE SUPER EARLY BIRD PRICE
$699
Register and pay by March 1, 2019. Save $300.
2 day conference pass
Must be a full time academic or healthcare professional
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Tom Ledward, [email protected]
Tuesday, December 18, 2018 to Friday, March 1, 2019
ACADEMIA, GOVERNMENT AND HEALTHCARE SUPER EARLY BIRD PRICE INCLUDING MACHINE LEARNING DAY
$999
Register and pay by March 1, 2019. Save $200.
3 day conference pass including Machine Learning Day
Must be a full time academic or healthcare professional
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Tom Ledward, [email protected]
Preparing registration...

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us

We need some information to know how best to respond to your request below.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.